Background. Clinical investigators from Seattle, Honolulu, Tokyo, and Hiroshima participated in two standardization exercises in which data were collected on independent assessments. Exercises were conducted to evaluate the interobserver agreement on clinical diagnoses of dementia and dementia subtypes in a cross-national study of dementia prevalence and incidence rates in the United States and Japan.
M
IGRATION of populations provides a unique opportunity to study genetic and environmental risk factors for chronic diseases. It also provides the opportunity to observe evolving care patterns in different cultures. When ethnic populations migrate into new cultures, they often experience relatively sudden changes in environment and lifestyle. Nonetheless, they tend to maintain the genetic homogeneity that distinguishes them from the majority population for at least several generations. Research projects focused on the relative influence of genetic and environmental factors or the interactive effects of multiple risk factors in ethnic groups can be enlightening, especially when the populations are studied in multiple locations across a historical migratory path.
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mately, identification of environmental risk factors for stroke and heart disease in this genetically homogeneous group led to general behavior recommendations to reduce disease risk, including modifying dietary and smoking habits. Such cross-cultural studies also have provided valuable information on disease symptomatology, medical service utilization of minority and ethnic groups, and factors associated with successful aging (5) .
Dementing illnesses present another interesting area for cross-cultural research in Japanese populations. Traditionally, vascular disease has been considered the most common cause of dementia in Japan, whereas Alzheimer's disease is the most common cause in the largely Caucasian populations of North America and Western Europe. Although overall dementia prevalence rates in Japan and the United States are similar, preliminary reports indicate that the composition of dementia subtypes is different. In Japanese studies, between 30% and 60% of dementia cases are attributed to vascular causes, and approximately half this level are attributed to Alzheimer's disease (6) . By contrast, most European and North American populations are reported to have 50-70% of dementia cases due to Alzheimer's disease, whereas only 12-20% are attributed to vascular causes.
This set of observations led to the establishment of a study in Seattle (The Kame Project) of the prevalence and incidence of dementia and its subtypes in the Japanese American population of King County, Washington state. This study was planned and developed in collaboration with investigators in Honolulu (The Honolulu Aging Study), Hiroshima (Hiroshima Radiation Effects Research Foundation), and Tokyo, Japan. The goal of these studies, which are collectively called the Ni-Hon-Sea Study, is to identify whether rates and causes of dementia are the same or different across cultures. If the rates are different, the groups will be especially interested in the discovery of modifiable risk factors. The Ni-Hon-San study played a role in the identification of important risk factors for coronary heart disease and cerebral vascular disease and helped reduce the burden of these chronic diseases in both the United States and Japan. It is expected that identification of risk factors for dementia would likewise lead to the development of preventive measures to delay onset or to prevent its occurrence altogether.
For this research to be successful, however, standardization of procedures, particularly for case detection and diagnosis, is essential. One explanation of previously reported differences in disease rates has been different diagnostic criteria or differences in the application of the criteria themselves. This report describes the standardization efforts and results of the cross-cultural, cross-national study of elderly Japanese in Hiroshima, Tokyo (Ni), Honolulu (Hon), and Seattle (Sea). Specific details about the planning, organization, and conduct of individual participant studies are available elsewhere (7, 8) . We briefly describe the history of the project and then focus on the standardization process that evolved around case detection and diagnosis and the steps we used to resolve problem areas of disagreement. We also identify future areas of investigation that are needed to advance our understanding of cognitive function in aging societies around the world.
METHODS
Background
The University of Washington Alzheimer's Disease Research Center sponsored a visit of Japanese investigators to Seattle in September 1987. This one-day meeting included representatives from the Japanese American community in King County as well as scientific investigators; it was the beginning of a series of preliminary discussions concerning a collaborative study on dementia in the United States and Japan. In August 1988, the National Institute on Aging (NIA) released a request for applications for "cross-national investigations of the epidemiology of Alzheimer's disease and other dementias of later life" that would support research "in other countries, cultures, ethnic or population groups, with different exposures and habits . . . that may offer clues to the etiology of the disease that are not available here. The need to search more aggressively and widely for potent modifiable risk factors requires movement beyond national boundaries."
Over the next several years, a series of international meetings including United States and Japanese investigators was held to develop a set of common research goals, standardized research methods, screening and diagnostic procedures, and plans for ultimate collaborative analyses. These efforts included development of the Cognitive Abilities Screening Instrument (CASI) (9), a 100-point measure intended for use with literate populations in cross-national studies of dementia. The CASI combines two of the most commonly used screening tests in the United States and Japan (the Mini-Mental State Examination and the Hasegawa Dementia Rating Scale). During this time period, it was administered and validated with nondemented elderly cohorts in Hiroshima, Honolulu, and Seattle (9, 10) .
In 1991, Seattle investigators received a 5-year NIA award to study the prevalence and incidence of dementia among elderly Japanese Americans in Seattle. The study was named the Kame Project after the Japanese word for turtle, a symbol representing longevity in Japanese culture. After numerous activities with the local Japanese American community and a county-wide census to identify Japanese Americans over age 55, a total of 1,985 Japanese Americans participated in a baseline examination and were enrolled (7) .
Standardization Plan
Simultaneous with local efforts to launch the prevalence phase of the Kame Project, a standardization program was initiated to ensure that collaborating sites in Japan (Hiroshima and Tokyo) and the United States (Honolulu and Seattle) were collecting comparable and interpretable data. At a workshop in 1992, the core data collection procedures and measures were identified. Participants established a common set of research and standardization goals. Site visits to compare assessment and diagnostic procedures were conducted in Honolulu and at the sites in Japan in 1994. Standardization goals and steps that have been taken to achieve them are listed below for what has come to be known as the Ni-Hon-Sea study.
Standardization of forms, including screening tests, neuropsychological assessment, and risk factor data acquisi-
tion.-A core set of instruments was identified for use at all sites, including the CASI for screening, the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological test battery (11), the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) (12) , and the Clinical Dementia Rating Scale (CDR) (13) to assess severity of dementia. In addition, sites followed CERAD clinical examination protocols, which specify the medical and family history, physical evaluation, and laboratory and neuroimaging tests (including head CT or MR) needed to derive a standardized dementia diagnosis (11, 14, 15) . Dr. Homma and bilingual study interviewers from Seattle translated forms into Japanese. An independent translator provided back-translations for content comparisons between Japanese versions used at the various sites.
Standardization of interviews.-Cross-site visits were scheduled for clinical staff to allow observation of interviews, neuropsychological testing, and physical examinations. Training tapes in English and Japanese were created for the neuropsychological battery and physical examination.
Analysis of CASI validity, reliability, sensitivity and specificity across sites.-Because variable population characteristics, particularly age and level of education, could impact CASI scores, it was necessary to check performance of the instrument at each site. As expected, some calibration of cutoff scores was needed across sites to attain a similar level of sensitivity of the instrument to detect dementia cases, using clinical diagnosis by consensus committee as the "gold standard" against which the CASI was measured (9) .
Standardization of dementia diagnostic procedures.-
Researchers in the Ni-Hon-Sea studies participated in diagnostic consensus meetings during cross-site visits, providing an opportunity to review how clinical data were interpreted, differences in background data (e.g., imaging studies) that were available at each site, and which dementia subtypes were most problematic for achieving multisite agreement. The group decided that only moderate to severe cases of dementia would be counted, that is, cases in which a subject received a combined diagnosis of dementia using DSM-III-R criteria (16) and a dementia impairment severity rating (CDR) score of 1 or greater. This case detection approach recognizes the difficulty of reliable detection in early dementia cases and also minimizes the number of false positives diagnosed.
At the 1994 Japan and Honolulu site visits, participants developed a plan for a series of standardization workshops at which teams of investigators from all sites would meet to review cases and develop common diagnostic/interpretation criteria for problematic situations. Two such standardization workshops have been completed to date (1995 in Seattle, 1996 in Tokyo). Prior to both workshops, all sites were sent a package of subject records including clinical dictations, neuropsychological test data, and other pertinent data that had been used in the consensus diagnosis (such as CT scan films). Investigators at each site reviewed all records and arrived at a DSM-III-R diagnosis for each subject before convening with the larger group. For those diagnosed as demented, raters determined whether the cause of dementia was primary degenerative dementia of the Alzheimer's type (AD), multi-infarct dementia (MID), or some other etiology. At each workshop, agreements and differences among sites were discussed, differences were resolved wherever possible, and diagnostic "rules" or conventions were established to minimize discrepancies in the future. Results from these two standardization meetings are summarized below.
Statistical Methods
For the 1995 standardization workshop in Seattle, a total of 55 subject records were reviewed by participants from each of the four primary sites (see Appendix A). In the 1995 exercise, all records were provided by the Seattle site. Records were selected in a stratified manner to provide a proportional representation of nondemented and demented (AD, MID, dementia, type other) subjects from the prevalence phase of the Kame Project. For the 1996 exercise, a total of 30 subjects were reviewed. Half of these were provided by Seattle and half by Honolulu. The Seattle site selected subjects at random in a stratified manner from the incidence phase of sampling, and the Honolulu site provided the first 15 subjects sampled for clinical workup. Subjects from the combined 85 charts ranged from 67 to 98 years (mean 82.2); 64% were women, and 27% lived in nursing homes or assisted living facilities.
Level of diagnostic agreement among the four rating sites was measured using the kappa statistic, which measures agreement over and above that occurring by chance, and percentage agreement statistics. Three subjects in 1995 and one in 1996 were not included in these computations because of missing diagnoses from one site. Kappa statistics were calculated to take into account multiple sites formulating multiple diagnoses (17) based upon four DSM-III-R groups (no dementia, AD, MID, unspecified dementia). Following the interpretation guidelines of Rosner (18) , kappa values higher than .75 denote excellent interrater agreement, those from .40 to .75 denote good agreement, and those below .40 denote marginal agreement. Kappa statistics were compared using the normal approximation method (17) . Table 1 shows agreement among the four sites on the diagnosis of dementia syndrome (dementia/no dementia). For all combinations of rating sites, agreement improved between the two standardization years. All individual kappa indices reached statistical significance, and the overall kappa agreement among sites was significantly higher (p < .0001) in 1996 than in 1995 (Table 1) . Table 2 summarizes the intersite reliability of the clinical diagnosis of dementia subtype. When computing kappa statistics, less common dementia variants (e.g., dementia secondary to alcoholism or Parkinson's disease), dementia cases with unknown etiology, and "mixed" dementia cases (most commonly those with a suspected combination of AD and vascular causes) were combined under the "dementia, type other" category. Mean kappa scores were lower than for dementia/no dementia comparisons, illustrating the increased difficulty in achieving agreement for diagnostic subtypes. Nevertheless, statistically significant improvement in overall kappa agreement was observed between the two standardization years (p = .0001), and by 1996 all individual kappa indices were within the good to excellent range. It should be noted that kappa statistics generated using all diagnoses (i.e., without grouping miscellaneous diagnoses into the "dementia, type other" category) were essentially identical to those presented in Table 2 .
RESULTS
Another measure of diagnostic reliability is percent agreement on a given diagnosis. In this study, the diagnosis used for comparison purposes was the one given by whichever site originally examined each patient and provided records for standardization review. To the extent that the examining site should be most likely to know each patient's "true" diagnosis, this procedure reflects the extent to which other sites were able to agree on this correct diagnostic classification. The most conservative approach to computing agreement calculates the number of cases where all four reviewing sites agree upon a clinical diagnosis. For exam- pie, in 1995 (Table 3) , of the 12 patients diagnosed with AD by the referring site (Seattle), there was perfect agreement on diagnosis in 25% of the cases (4/12). Additionally, a "gold standard" percent agreement was computed, which compared the diagnosis provided by the referring site (Seattle in 1995, Seattle or Honolulu in 1996) with the remaining three sites. This makes it possible to evaluate the percent agreement among all sites for all patients, including those where agreement was mixed. For example, in 1995, there was 56% agreement on the diagnosis of AD (20/36 agreeing diagnoses provided by three sites for 12 subjects). Using either approach, it can be seen that, for most categories, agreement improved between the two standardization years. Identification of nondemented cases yielded the best agreement. Agreement on dementia subtypes varied, with best agreement for multi-infarct dementia, followed by Alzheimer's disease and all other diagnostic categories (dementia, type other). Much of the disagreement in this latter category arose from cases in which patients had multiple potential contributing causes to their cognitive decline. For example, sites varied in their interpretations of whether insidious decline leading to a diagnosis of AD occurred prior to the onset of closed head injury, or whether the presence of small lucencies on MRI films was sufficient to place a subject into a "mixed" AD/MTD category rather than simple AD. At each year's meeting, discrepancies between sites were discussed, and attempts were made to resolve them. These efforts were generally successful. For example, in 1995, of 11 charts considered "no dementia" by the Seattle site, only 5 (45%) were initially rated by all other sites as nondemented (perfect concordance); following the standardization discussion, the sites had reached full agreement on 10 of the 11 (91%) charts. During the discussion, diagnostic conventions or "rules" (Appendix B) were developed to help guide sites in future diagnostic comparisons and standardization meetings; the effectiveness of these conventions is demonstrated by the improved kappa statistics and percent agreement values in 1996. 
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DISCUSSION
In this cross-national study of dementia diagnosis in elderly Japanese subjects, clinical investigators participated in a series of meetings designed to ensure that data were being collected in a comparable and interpretable way. The results of two standardization workshops (during which each site arrived at criteria-based diagnoses for 85 subjects based on review of standard medical record and neuropsychological test data) demonstrate that it is possible to achieve an acceptable level of agreement on clinical diagnosis in cross-national studies of dementia.
The sites achieved good kappa statistics and percent agreement levels (Tables 1-3 ). The level of agreement observed was consistent with data reported in other studies of cross-national, dementia interobserver agreement (19) (20) (21) . Highest agreement levels were achieved with regard to the presence or absence of dementia. Agreement on subtypes varied, with the best agreement levels reported for vascular dementia and Alzheimer's disease and the worst agreement levels for other diagnostic categories. Agreement levels improved in 1996 compared to the 1995 results, despite the fact that the 1996 exercise included incident cases of dementia, which are more difficult to classify because of the reduced historical information available for diagnosis as well as the fact that persons with a recent onset of dementia perform better on tests of cognitive and functional status than persons with more advanced disease. We believe this improvement reflects group learning from the previous consensus exercises, adherence to the diagnostic conventions developed during the 1995 meeting, and the shared knowledge the group gained of unique characteristics like education, lifestyle, and other features of the different cultures and sites.
Because individual differences between sites affected overall estimates of reliability, a goal of the standardization meetings was to clarify sources of disagreement. At closer examination, discrepancies between sites were often due to issues of data quality and interpretation. For example, critical information needed to make a DSM-III-R dementia diagnosis (e.g., documentation of remote memory loss or a decline in daily functioning) was sometimes omitted from interview dictations, making it difficult for clinicians who had not personally examined the patient to endorse diagnostic criteria. Sites differed in how they interpreted more subjective diagnostic criteria, such as what constituted "significant" interference with social or occupational functioning or whether inability to remember what one had for breakfast should be considered short-or long-term memory loss. Sites also varied in the emphasis they placed on multiple sources of information (medical records, physician interview, proxy/family report, or cognitive test results), particularly when sources apparently disagreed or contradicted one another. Finally, clerical data coding errors were a source of discrepancy (e.g., marking "no dementia" when "dementia, type other" was intended); because subject records and consensus diagnosis forms were provided in English for the standardization meetings, language differences may have contributed to an increased error rate risk. As these, as well as other between-site differences were identified, attempts were made to generate diagnostic conventions or "rules" to overcome them. The demonstrated improvement from 1995 to 1996 illustrates the importance of training and standardization in the use of diagnostic criteria such as the DSM-III-R.
Among types of dementia, the most common source of disagreement revolved around distinguishing dementia secondary to vascular causes from dementia due to another or an unknown cause (e.g., presumed Alzheimer's disease). During standardization exercises, participants reported noteworthy differences in local medical styles regarding the clinical diagnosis of stroke, particularly for vague symptoms such as dizziness, weakness, blurred vision, or changes in memory. Thus, patients' self-reports of "stroke," and even physicians' reports of stroke and review of medical records, were difficult to compare. It was necessary to standardize the interpretation of clinical signs and symptoms, as well as the interpretation of neuroimaging findings. For example, we adopted the convention that nonlocalizing neurologic symptoms (such as dizziness or sudden generalized weakness) did not qualify for a diagnosis of stroke or transient ischemic attack (TIA). We believe the development of these conventions, along with more careful recording of clinical data, led to the improvement in agreement regarding rates of vascular dementia and Alzheimer's disease in the 1996 exercise. Diagnostic reliability in cross-national studies of dementia also may be influenced by the type of standardized diagnostic , criteria used (22) . In 1994, the DSM-III-R was superseded by / DSM-IV. Although most criteria remain essentially the same,/ two changes in DSM-IV could affect case defection and diagnosis. The first is the relaxation in memory criteria for dementia; in DSM-IV, recent or remote memory loss is a diagnostic criterion, compared with recent and remote memory loss requirements in DSM-III-R. The second change is that DSM-IV allows for the option of diagnosing dementia due to multiple etiologies, such as AD and stroke, rather than forcing a distinction between them. In spite of this, the lack of generally accepted criteria for vascular dementia remains a problem in studies such as the Ni-Hon-Sea Study. We have chosen to deal with this problem by encouraging all study sites to use both versions of DSM; in addition, investigators in Honolulu and Seattle are completing essentially all available diagnostic criteria for vascular dementia, including the DSM-m-R, CERAD, NINDS (23), California (24) , and criteria developed by Ni-Hon-Sea neurologists in Seattle and Honolulu. Completion of the various criteria is cumbersome, however, and the field will clearly benefit when the performance of these criteria in this setting is known. /
We expect that other lines of research will improve the / reliability of future cross-national studies of dementia.-Most important for our study is the opportunity for longitudinal follow-up, particularly of those difficult cases with isolated memory loss or borderline dementia. Following such persons over time will likely lead to more accurate diagnostic classifications, as most forms of dementia tend to be generally progressive. Persons who die between follow-up visits, of course, will continue to be unclassifiable. In addition, as we learn more about the performance of the CASI in different cultures, there will likely be greater reliability in the detection of dementia, including mild cases. Research to standardize the interpretation of vascular crite-ria and neuroimaging, including CT and MRI, will improve diagnostic rates, as will systematic comparison with autopsy results. Improved understanding of the interrelationship between changes in brain circulation and the onset of illnesses such as Alzheimer's disease will also enhance our clinical ability to classify persons as having vascular or Alzheimer's type dementia.
Finally, because our standardization exercises to date have been based on review of materials from Seattle and Honolulu only, future work to demonstrate the diagnostic agreement across sites for Japan-based records will be needed to establish definitively that cross-national diagnostic reliability has been achieved. Nevertheless, our early findings are promising, and we expect that studies of aging and dementia in the Pacific Rim will grow. For example, since the Ni-HonSea study was developed, investigators from Taiwan (see Appendix A) have adopted a similar methodology to study the prevalence and incidence of dementia in a largely rural population on the islet of Kinmen.
Conclusion
In summary, cross-cultural studies of the epidemiology of Alzheimer's disease and related disorders require the development of standardized sampling, assessment, data handling, and diagnostic procedures. To be successful, such studies must also show that diagnostic outcomes are reliable across sites. The standardization exercise of the NiHon-Sea study reported in this article demonstrates that investigators from different cultures can achieve acceptable levels of interrater agreement. Such agreement is important if we are to learn from the unique opportunity that migration of ethnic populations affords in understanding dementia and aging.
